文献速递妇产影像介入USMR

初步研究:单纯超声引导高强度聚焦超声消融直径大于10厘米子宫肌瘤的安全性与有效性

Pilot study: safety and effectiveness of simple ultrasound-guided high-intensity focused ultrasound ablating uterine leiomyoma with a diameter greater than 10 cm.
PubMed 文献 · Br J Radiol · 2017-11-21

前瞻性分析36例直径大于10厘米的症状性子宫肌瘤患者,单次单纯超声引导高强度聚焦超声治疗,治疗前后行增强MRI并随访6个月。结果显示消融率71.9±20.4%,6个月肌瘤消退率40.8±7.5%,症状严重评分平均下降约8.6±2.3分,无严重不良反应;作者认为单次单纯USgHIFU安全有效,可能是有前景的治疗策略。

要点

  • 直径大于10厘米子宫肌瘤可尝试单次单纯USgHIFU治疗,本组消融率71.9±20.4%。
  • 治疗后6个月肌瘤消退率40.8±7.5%,症状严重评分平均下降约8.6±2.3分。
  • 除天冬氨酸氨基转移酶、总胆红素和白细胞一过性升高外,血常规与血生化无明显变化,无严重不良反应。

核心结论

  • 根据作者初步结果,单纯USgHIFU是治疗直径大于10厘米子宫肌瘤安全有效的单次治疗方法,几乎无创的替代治疗策略。

研究设计与样本

  • 前瞻性研究,共36例患者36个症状性子宫肌瘤(直径大于10厘米),仅接受单纯USgHIFU治疗;治疗前后行增强MRI,所有患者随访6个月。

关键影像表现/征象

  • 肌瘤平均直径11.2±1.3厘米(范围10.0-14.3厘米)。
  • 中位治疗时间104.0分钟(范围90.0-140.0分钟),中位治疗速度118.8 cm3 h-1(范围86.2-247.1 cm3 h-1)。
  • 肌瘤消融率71.9±20.4%(范围32.1-100.0%),治疗后6个月肌瘤消退率40.8±7.5%(范围25.6-59.9%)。
  • 症状严重评分平均下降约8.6±2.3分(范围5-14分)。
  • 治疗后天冬氨酸氨基转移酶、总胆红素和白细胞一过性升高,血常规与血生化其他指标无明显变化,无严重不良反应。

临床应用与阅片要点

  • 作者认为单纯USgHIFU可作为直径大于10厘米子宫肌瘤的单次治疗选择,安全有效且几乎无创。
  • 治疗后需关注天冬氨酸氨基转移酶、总胆红素和白细胞的一过性升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The study aimed to prospectively investigate whether uterine leiomyoma greater than 10 cm in diameter could be treated with simple ultrasound-guided high-intensity focused ultrasound (USgHIFU) in one-time treatment.

METHODS: A total of 36 patients with 36 symptomatic uterine leiomyoma greater than 10 cm in diameter who underwent simple USgHIFU treatment alone were analysed. Enhanced MRI was performed before and after HIFU treatment, and all patients had follow-up for 6 months after treatment. Symptom severity scores, treatment time, treatment speed, ablation rate, energy effect ratio, uterine leiomyoma regression rate, adverse events, liver and kidney functions, coagulation function and routine blood count were included in the study endpoints.

RESULTS: The mean diameter of uterine leiomyoma was 11.2 ± 1.3 cm (10.0-14.3 cm). The median treatment time and treatment speed were 104.0 min (90.0-140.0 min) and 118.8 cm3 h-1 (86.2-247.1 cm3 h-1), respectively. The ablation rate of uterine leiomyoma was 71.9 ± 20.4% (32.1-100.0%), and the regression rate of uterine leiomyoma was 40.8 ± 7.5% (25.6-59.9%) at 6 months after treatment. The mean symptom severity scores decreased by an average of approximately 8.6 ± 2.3 (5-14) points. There were no significant changes in haemogram and blood chemical indexes of patients, except for the transient elevation of aspartate aminotransferase, total bilirubin and white blood cells after treatment. No serious adverse reactions occurred.

CONCLUSION: According to our preliminary results, simple USgHIFU is a safe and effective single-treatment method of treating uterine leiomyoma greater than 10 cm in diameter and is an almost innocuous alternative therapeutic strategy. Advances in knowledge: The conclusions indicate simple USgHIFU is safe and effective as one-time treatment of uterine leiomyoma greater than 10 cm in diameter, it could be a promising therapeutic strategy.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Hou R, Wang L, Li S, et al. Pilot study: safety and effectiveness of simple ultrasound-guided high-intensity focused ultrasound ablating uterine leiomyoma with a diameter greater than 10 cm. Br J Radiol. 2017. PMID: 29091474. doi:10.1259/bjr.20160950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。